New­ly de­buted biotech shoots for $40M IPO; In­tel­lia touts new an­i­mal da­ta on CRISPR/Cas9

⇨ Just 8 months af­ter mak­ing its de­but at the be­gin­ning of the year, Cam­bridge, MA-based Cue Bio­phar­ma has filed for a $40 mil­lion IPO. The TCR com­pa­ny is based on work done at Al­bert Ein­stein Col­lege of Med­i­cine. The biotech win­dow has opened con­sid­er­ably in the last few months, but a fledg­ling com­pa­ny like this could well test in­vestors’ ap­petite for the un­known. Ac­cord­ing to the S-1, they’re still in­volved in pre­clin­i­cal work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.